Cite

HARVARD Citation

    Kok, P. et al. (2022). Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma—a phase 3 randomised trial. BMJ open. 12 (1), p. . [Online]. 
  
Back to record